Committee to Save Novavax – ‘DFAN14A’ on 3/23/05 re: Novavax Inc

On:  Wednesday, 3/23/05, at 5:20pm ET   ·   Effective:  3/23/05   ·   Accession #:  1068800-5-198   ·   File #:  0-26770

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Additional Definitive Non-Management Proxy Solicitation Material   —   Schedule 14A
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: DFAN14A     Additional Definitive Non-Management Proxy             2±     9K 
                          Solicitation Material                                  

DFAN14A
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SCHEDULE 14A INFORMATION    

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [ ]                                                     

Filed by a Party other than the Registrant [X]                                  

Check the appropriate box:                                                      
[ ]  Preliminary Proxy Statement                                                
[ ]  Confidential, for Use of the Commission Only (as permitted by              
Rule 14a-6(e)(2))                                                     
[ ]  Definitive Proxy Statement                                                 
[ ]  Definitive Additional Materials                                            
[X] Soliciting Material Pursuant to Section 240.14a-12                          

NOVAVAX, INC.   
(Name of Registrant as Specified in Its Charter)    

COMMITTEE TO SAVE NOVAVAX   
(Name of Person Filing Proxy Statement if other than the Registrant)    

Payment of Filing Fee (Check the appropriate box):                              

[X] No fee required.                                                            

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.    

(1) Title of each class of securities to which transaction applies: 
(2) Aggregate number of securities to which transaction applies:    
(3) Per unit price or other underlying value of transaction computed
         pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):  
(4) Proposed maximum aggregate value of transaction:                
(5) Total Fee paid:                                                 

[ ] Fee paid previously with preliminary materials.                             

[ ] Check box if any part of the fee is offset as provided by Exchange          
Act Rule 0-11(a)(2) and identify the filing for which the offsetting    
fee was paid previously. Identify the previous filing by registration   
statement number, or the Form or Schedule and the date of its filing.   

(1) Amount Previously Paid:                                             
(2) Form, Schedule or Registration Statement No.:                       
(3) Filing Party:                                                       
(4) Date Filed:                                                         

THE COMMITTEE TO SAVE NOVAVAX   

STOP!   
DO NOT SIGN A WHITE PROXY CARD    
---                         

March 23, 2005                                                                  

Dear Fellow Novavax Shareholder:                                                

You will shortly receive proxy materials from management of   
Novavax, Inc., seeking your votes for the re-election of two director           
nominees; Denis M. O'Donnell and Nelson M. Sims at the May 4, 2005 Annual       
Shareholder Meeting. We urge you NOT TO VOTE FOR THESE NOMINEES!                

     We are the Committee to Save Novavax and we will shortly be mailing
to you complete proxy materials seeking your proxy vote for our two             
alternative directors. In these materials we will clearly describe to you       
our plan to stabilize company performance and build value for shareholders      
of Novavax.                                                                     

THE TIME FOR CHANGE IS NOW!   
DON'T LET THE CURRENT BOARD LEADERSHIP DESTROY ANY MORE SHAREHOLDER VALUE   

The Committee to Save Novavax is committed to protecting the  
interests of all shareholders and will keep you apprised of important           
developments as they occur. Once we have cleared SEC regulatory                 
requirements, you will be able to learn more at our website,                    
www.SaveNovavax.com.                                                            

Sincerely,                                                                      

The Committee to Save Novavax                                                   

------------------------------------------------------------------------------- 
If you have any questions or need assistance, please contact the following firm 
who will be assisting us in the solicitation of proxies:    

GEORGESON SHAREHOLDER COMMUNICATIONS INC.   
17 State Street, 10th Floor   
New York, New York 10004    
Toll Free: (800) 676-0151   
Banks and Brokers call: (212) 440-9800    
------------------------------------------------------------------------------- 

J. Carter Williams, Melissa Georges, William Georges and John T. Preston are    
the participants in the Committee's proxy solicitation. You may obtain          
additional information about their interests by calling Georgeson at the        
number listed above and asking that a copy of the Committee's preliminary       
proxy statement filed with the SEC be sent to you. You should read the proxy    
statement when it becomes available because it contains important               
information. You can get the proxy statement for free at the SEC's web site,    
www.sec.gov.                                                                    

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘DFAN14A’ Filing		Date		Other Filings
		5/4/05		3,  4,  DEF 14A,  PRE 14A
Filed on / Effective on:		3/23/05
				List all Filings